Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

Kymera Therapeutics, Inc.7 enrolled

Overview

This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non Hodgkin Lymphoma Diffuse Large B Cell Lymphoma DLBCL MYD88 Gene Mutation

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Phase 1a Only: * Histologically confirmed diagnosis of B-cell NHL according to the 2016 World Health Organization (WHO) classification. Diffuse large B-cell lymphoma (DLBCL) includes: DLBCL not otherwise specified (NOS) with or without MYC and BCL2 and/or BCL6 rearrangements; Epstein-Barr virus (EBV) positive DLBCL, NOS; human herpesvirus 8 (HHV8) positive DLBCL, NOS; DLBCL associated with chronic inflammation; and Primary cutaneous DLBCL, leg type. Patients with indolent lymphoma are eligible if they meet criteria for systemic treatment. * Clinicopathological diagnosis of Waldenström's Macroglobulinemia (WM) based on the consensus panel criteria from the Second International Workshop on WM * Histologically/cytologically confirmed relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL) by cerebrospinal fluid (CSF) or biopsy. PCNSL patients are considered eligible if the Investigator believes that there is no other reasonable treatment alternative. * Note: Patients with HIV-associated PCNSL are not eligible. * Note: Patients with secondary CNS metastases are eligible assuming they meet other study criteria. Patients with secondary CNS metastases include those who have synchronous systemic and CNS involvement or those who have been previously treated and relapsed with isolated CNS involvement. * Phase 1b Only: Histologically confirmed diagnosis of DLBCL according to the 2016 WHO classification including: DLBCL not otherwise specified (NOS) with or without MYC and BCL2 and/or BCL6 rearrangements; Epstein-Barr virus (EBV) positive DLBCL, NOS; HHV8+ DLBCL, NOS; DLBCL associated with chronic inflammation; and Primary cutaneous DLBCL, leg type. * Disease relapsed and/or refractory to at least 2 accepted standard systemic regimens for all indications except PCNSL. For PCNSL, patients must be relapsed and/or refractory to at least 1 prior regimen. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening. * Adequate organ and bone marrow function, in the absence of growth factors * Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol Exclusion Criteria: * Infection with hepatitis B (HBV), hepatitis C (HCV), or active viral infection with human immunodeficiency virus (HIV). * Radiation treatment within 4 weeks prior to first dose of study drug, unless the tumor site continues to increase in size after the patient has completed radiotherapy treatment. * Major surgery requiring general anesthesia within 4 weeks prior to first dose of study drug, unless the tumor site continues to increase in size after the patient has completed radiotherapy treatment. * Ongoing unstable cardiovascular function including history of myocardial infarction within 3 months of planned start of study drug. * Patient has not recovered from any clinically significant AEs of previous treatments to pre-treatment baseline or Grade 1 prior to first dose of study drug.

Locations (8)

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, United States

Norton Cancer Institute

Louisville, Kentucky, United States

Henry Ford Health System

Detroit, Michigan, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

MD Anderson Cancer Center

Houston, Texas, United States

University of Virginia Comprehensive Cancer Center

Charlottesville, Virginia, United States

University College London Hospitals

London, United Kingdom

University Hospital Southampton NHS Foundation Trust

Southampton, United Kingdom

Outcomes

Primary Outcomes

To establish the Maximum Tolerated Dose (MTD)

Phase 1a

Time frame: Within first 3 weeks of treatment

Number of Participants with protocol specified Dose Limiting Toxicities (DLTs)

Phase 1a

Time frame: Within first 3 weeks of treatment

Dose recommended for future studies

Phase 1a/1b

Time frame: Within first 3 weeks of treatment

Clinical Laboratory Abnormalities

Incidence and severity of clinical laboratory abnormalities in serum chemistry, hematology, coagulation parameters, and urinalysis tests as assessed by CTCAE v5.0 (Phase 1a/1b)

Time frame: Clinical laboratory abnormalities will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy

Adverse Event Parameters

Incidence and severity of adverse events as assessed by CTCAE v5.0 (Phase 1a/1b)

Time frame: Adverse Event Parameters will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy

ECG Parameters

Changes in the ECG parameters, including heart rate and measures PR, QRS, QT, and QTc intervals as assessed by CTCAE v5.0 Phase 1a/1b

Time frame: ECG Parameters will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy

Secondary Outcomes

Area under the plasma concentration versus time curve for KT-413 from time zero to last quantifiable time point (AUC0-t)

Phase 1a/1b

Time frame: Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)

Maximum Plasma Concentration of KT-413 (Cmax)

Phase 1a/1b

Time frame: Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)

Time of maximum plasma concentration of KT-413 (Tmax)

Phase 1a/1b

Time frame: Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)

Half-life of KT-413 [if data permits (T1/2)]

Phase 1a/1b

Time frame: Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 21 days)

Amount of KT-413 excreted in urine from time zero to last collected timepoint (Ae0-t)

Phase 1a/1b

Time frame: Urine samples for PK analysis collected during the first cycle (21 day cycle)

Evidence of clinical activity of KT-413 as determined by Objective Response Rate (ORR)

Phase 1a/1b

Time frame: From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months

Duration of Response (DOR) as assessed by the Investigator

Phase 1a/1b

Time frame: From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months

Progression-free survival (PFS) as assessed by the Investigator

Phase 1b

Time frame: From time of entry on study through progression, up to 18 months

Disease Control Rate (DCR) as assessed by the investigator

Phase 1b

Time frame: From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months

Overall Survival (OS) as assessed by the investigator

Phase 1b

Time frame: From time of entry on study through death or date last known alive at end of follow-up, up to 18 months